Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-08-21
2007-08-21
Tsang, Cecilia J. (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S324000
Reexamination Certificate
active
10551005
ABSTRACT:
Heparin-binding peptides are provided of the formula R1(X1B1B2X2B3X3Y1R2)RnR3, R1(X1B1B2B3X2X3B4X4Y1R2)RnR3, and C(X1B1B2B3X2X3B4X4)nC; wherein X1, X2, X3, and X4are independently selected from the group consisting of hydropathic amino acids; B1, B2, B3, and B4are independently selected from the group consisting of basic amino acids; C is cysteine; Y1is zero or one to ten amino acid residues, wherein at least one amino acid residue is proline; n is an integer from one to ten; and R1, R2, and R3are independently selected segments containing from zero to twenty amino acid residues, provided, at least one of the segments R1, R2, and R3comprises at least one hydrophobic amino acid residue. The peptide C(X1B1B2B3X2X3B4X4)nC is optionally cyclized via a disulfide bond formed between cysteine residues. The peptides are administered to reduce plasma LMWH and heparin levels and to reduce the anticoagulant effects of heparin and LMWH. The peptides are also administered to inhibit microbial growth and to inhibit mast cell serine proteases involved in various diseases and disorders. The peptides are also administered as carriers to deliver active agents.
REFERENCES:
patent: 4829000 (1989-05-01), Kleinman et al.
patent: 5238919 (1993-08-01), Zimmerman et al.
patent: 5332671 (1994-07-01), Ferrara et al.
patent: 5380716 (1995-01-01), Conrad et al.
patent: 5409897 (1995-04-01), Thomas et al.
patent: 5464815 (1995-11-01), Chamow et al.
patent: 5510328 (1996-04-01), Polarek et al.
patent: 5556836 (1996-09-01), Roedern et al.
patent: 5770563 (1998-06-01), Roberts et al.
patent: 5849689 (1998-12-01), Chamow et al.
patent: 5851989 (1998-12-01), Chamow et al.
patent: 5877153 (1999-03-01), Harris et al.
patent: 5968822 (1999-10-01), Pecker et al.
patent: 6194558 (2001-02-01), Gianturco et al.
patent: 6395707 (2002-05-01), Zioncheck et al.
patent: 6855801 (2005-02-01), San Antonio et al.
patent: 2003/0069170 (2003-04-01), Soltero et al.
patent: WO95/13083 (1995-05-01), None
patent: WO97/47312 (1997-12-01), None
patent: WO 00/45831 (2000-08-01), None
D.V. Sakharov et al., “Binding And Retention Of Polycationic Peptides And Dendrimers In The Vascular Wall”,FEBS Letters, 537, 2003, pp. 6-10.
A. Lundequist et al., “Polycationic Peptides As Inhibitors Of Mast Cell Serine Proteases”,Biochemical Pharmacology, 65, 2003, pp. 1171-1180.
E. Andersson et al., “Antimicrobial Activities Of Heparin-Binding Peptides”,Eur. J. Biochem, 271, 2004, pp. 1219-1226.
A. Verrecchio et al., “Design Of Peptides With High Affinities For Heparin And Endothelial Cell Proteoglycans”,The Journal Of Biological Chemistry, 275, 2000, pp. 7701-7707.
B. Schick et al., “Novel Concatameric Heparin-Binding Peptides Reserve Heparin And Low-Molecular-Weight Heparin Anticoagulant Activities In Patient Plasma In Vitro And In Rats In Vivo”,Blood, 103, 2004, pp. 1356-1363.
S.C. Hodgkinson, “Glycosaminoglycan Binding Characteristics Of The Insulin-Like Growth Factor-Binding Proteins”,Journal Of Molecular Endocrinology, 13, 1994, pp. 105-112.
A.G. Gibson, et al., “Orientation Of Heparin-Binging Sites In Native Vitronectin”,The Journal Of Biological Chemistry, 274, 1999, pp. 6432-6442.
H. Conrad, “Heparin-Binding Proteins”, Academic Press, pp. 192-196.
M.A. Pinhal, et al., “Heparin And A Cyclic Octaphenol-Octasulfonic Acid (GL-522-Y-1) Bind With High Affinity To A 47-KDA Protein From Vascular Endothelial Cell Surface And Stimulate The Synthesis And Structural Changes Of Heparan Sulfate Proteoglycan”,Thromb Res, 103, 2001, pp. 35-45.
Z Mostafavi-Pour, et al., “Identification Of A Novel Heparin-Binding Site In The Alternatively Spliced IIICS Region Of Fibronectin: Roles Of Integrins And Proteoglycans In Cell Adhesion To Fibronectin Splice Variants”,Matrix Biol, 20, 2001, pp. 63-73. Abstract Only.
J Kappler et al., “Glycosaminoglycan-Binding Propertie And Secondary Structure Of The C-Terminus Of Netrin-I”,Biochem Biophys Res Commun, 271, 2000, pp. 287-291.
S.E. Sakiyama et al., “Incorporation Of Heparin-Binding Peptides Into Fibrin Gels Enhances Neurite Extension: An Example Of Designer Matrices In Tissue Engineering”,FASEB J., 13, 1999, pp. 2214-2224.
S. Liu et al., “A Peptide Sequence Of Heparin/Heparan Sulfate (HP/HS)-Interacting Protein Supports Selective, High Affinity Binding Of HP/HS And Cell Attachment”,Journal of Biol Chem, 273, 1998, pp. 9718-9726.
F. Chillemi et al., “Synthesis And Cytotoxic Activity Of New Peptides Containing Basic Amino Acid Residues”,Anticancer Res., 18, 1998, pp. 757-758.
R.E. Hileman et al., “Glycosaminoglycan-Protein Interactions; Definition of Consensus Sites In Glycosaminoglycan Binding Proteins”,Bioessays, 20, 1998, pp. 156-167.
J.R. Fromm et al., “Pattern And Spacing Of Basic Amino Acids In Heparin Binding Sites”,Arch Biochem Biophys343, 1997, pp. 92-100.
S. Liu et al., “A Heparin-Binding Synthetic Peptide Of Heparin/Heparan Sulfate-Interacting Protein Modulates Blood Coagulation Activities”,Proc. Natl. Acad. Sci., 94, 1997, pp. 1739-1744.
G.J. Taylor et al., “Glycosaminoglycan Specificity Of A Heparin-Binding Peptide”,Pept Res, 1995, pp. 286-293.
W.A. Patton 2ndet al., “Identification Of A Heparin-Binding Protein Using Monoclonal Antibodies That Block Heparin Binding To Porcine Aortic Endothelial Cells”,Biochem J, 311, 1995, pp. 461-469. Abstract Only.
K Mizuno et al., “Hairpin Loop And Second Kringle Domain Are Essential Sites For Heparin Binding And Biological Activity Of Hepatocyte Growth Factor”,J. Biol Chem, 269, pp. 1131-1136.
T.W. Wakefield et al., “Reversal Of Low-Molecular-Weight Heparin Anticoagulation By Synthetic Protamine Analogues”,J. Surgical Research, 56, 1994, pp. 586-593.
D.S. Ferran et al., “Design and Synthesis Of A Helix Heparin-Binding Peptide”,Biochemistry, 31, 1992, pp. 5010-5016.
A.D. Cardin, “Molecular Modeling Of Protein-Glycosaminoglycan Interactions”,Arteriosclerosis, 9, 1989, pp. 21-32.
B.R. Tomasini et al., “On The Identity Of Vitronectin And S-Protein: Immunological Crossreactivity And Functional Studies”,Blood, 68, 3, 1986, pp. 737-742.
H. Margalit et al., “Comparative Analysis Of Structurally Defined Heparin Binding Sequences Reveals a Distinct Spatial Distribution Of Basic Residues”,The Journal Of Biological Chemistry, 268, 1983, pp. 19228-19231.
H.C. deBoer, et al., “Binding Of Vitronectin-Thrombin-Antithrombin III Complex To Human Endothelial Cells Is Mediated By The Heparin Binding Site Of Vitronectin”,The Journal Of Biological Chemistry, 267, 1982, pp. 2264-2268.
J.M. McPherson, et al., “The Effects of Heparin on the Physicochemical Properties of Reconstituted Collagen”,Collagen Rel. Res., 1:65-82 (1998).
L.H. Lam, et al., “The Separation of Active and Inactive Forms of Heparin”,Biochem. Biophys. Res. Comm., 69(2):570-577 (1976).
J.D. San Antonio, et al., “Heparin Sensitive and Resistant Vascular Smooth Muscle Cells: Biology and Role in Restenosis”,Connective Tissue Research, 37(1-2):87-103.
J.S. San Antonio, et al., “Interactions of Syndecan-1 and Heparin with Human Collagens”,Glycobiology, 4(3):327-332 (1994).
U. Lindahl, et al., “Glycosaminoglycans and Their Binding to Biological Macromolecules”,Ann. Rev. Biochem., 47:385-417 (1978).
J. Lawler, et al., “The Structure of Human Thrombospondin, and Adhesive Glycoprotein with Multiple Calcium-Binding Sites and Homologies with Several Different Proteins”,J. Cell. Biology, 103:1635-1648 (1986).
E.C. Tsilibary, et al., “Heparin Type IV Collagen Interactions: Equilibrium Binding and Inhibition of Type IV Collagen Self-Assembly”,J. of Biological Chemistry, 263(35): 19112-19118 (1988).
F.J. Bober Barkalow, et al., “Localization of the Major Heparin-Binding Site in Fibron
San Antonio James D.
Schick Barbara P.
Verrecchio Angela
Audet Maury
Drinker Biddle & Reath LLP
Monaco Daniel A.
Thomas Jefferson University
Tsang Cecilia J.
LandOfFree
Heparin-binding peptides and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heparin-binding peptides and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heparin-binding peptides and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3894427